From 2010 to 2017 in Canada, excluding Quebec, HR+ accounted for 74% of BC cases in the population, and HR+/HER+, HER2+ and TN made up 10.4%, 4.9% and 10.7%, respectively. Here, ERBB2 is linked to breast cancer.